• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高滴度 COVID-19 恢复期血浆输注的生化原理。

Biochemical rationale for transfusion of high titre COVID-19 convalescent plasma.

机构信息

Transfusion Research Center, Belgian Red Cross-Flanders, Ghent, Belgium.

Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.

出版信息

Sci Rep. 2024 Oct 9;14(1):23579. doi: 10.1038/s41598-024-75093-x.

DOI:10.1038/s41598-024-75093-x
PMID:39384892
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11464705/
Abstract

We aimed to model binding of donor antibodies to virus that infects COVID-19 patients following transfusion of convalescent plasma (CCP). An immunosorbent assay was developed to determine apparent affinity (K). Antibody binding to virus was modelled using antibody concentration and estimations of viral load. Assay and model were validated using reference antibodies and clinical data of monoclonal antibody therapy. A single K or two resolvable K were found for IgG in 11% or 89% of CCP donations, respectively. For IgA this was 50%-50%. Median IgG K was 0.8nM and 3.6nM for IgA, ranging from 0.1-14.7nM and 0.2-156.0nM respectively. The median concentration of IgG was 44.0nM (range 8.4-269.0nM) and significantly higher than IgA at 2.0nM (range 0.4-11.4nM). The model suggested that a double CCP transfusion (i.e. 500 mL) allows for > 80% binding of antibody to virus provided K was < 1nM and concentration > 150nM. In our cohort from the pre-vaccination era, 4% of donations fulfilled these criteria. Low and mid-range viral loads are found early post exposure, suggesting that convalescent plasma will be most effective then. This study provides a biochemical rationale for selecting high affinity and high antibody concentration CCP transfused early in the disease course.

摘要

我们旨在建立模型,以预测在输注恢复期血浆(CCP)后,供体抗体与感染 COVID-19 患者的病毒的结合情况。开发了一种免疫吸附测定法来确定表观亲和力(K)。使用抗体浓度和病毒载量的估算值来模拟抗体与病毒的结合。使用参考抗体和单克隆抗体治疗的临床数据对测定法和模型进行了验证。在 11%或 89%的 CCP 捐赠物中,分别发现 IgG 有一个或两个可分辨的 K。对于 IgA,这一比例分别为 50%-50%。IgG 的中位数 K 为 0.8nM 和 3.6nM,而 IgA 的中位数 K 为 0.2-156.0nM。IgG 的中位数浓度为 44.0nM(范围为 8.4-269.0nM),明显高于 IgA 的浓度 2.0nM(范围为 0.4-11.4nM)。该模型表明,两次输注 CCP(即 500mL)可使抗体与病毒的结合率超过 80%,前提是 K<1nM 且浓度>150nM。在我们来自疫苗接种前时代的队列中,有 4%的捐赠物符合这些标准。在接触后早期发现低和中范围的病毒载量,这表明恢复期血浆在那时最有效。本研究为选择在疾病早期高亲和力和高抗体浓度的 CCP 输注提供了生化依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3db6/11464705/2bf66570e066/41598_2024_75093_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3db6/11464705/d4a9b5336ddc/41598_2024_75093_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3db6/11464705/302fa39b57e3/41598_2024_75093_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3db6/11464705/b5cc0cfefc81/41598_2024_75093_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3db6/11464705/195366aa959a/41598_2024_75093_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3db6/11464705/2bf66570e066/41598_2024_75093_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3db6/11464705/d4a9b5336ddc/41598_2024_75093_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3db6/11464705/302fa39b57e3/41598_2024_75093_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3db6/11464705/b5cc0cfefc81/41598_2024_75093_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3db6/11464705/195366aa959a/41598_2024_75093_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3db6/11464705/2bf66570e066/41598_2024_75093_Fig5_HTML.jpg

相似文献

1
Biochemical rationale for transfusion of high titre COVID-19 convalescent plasma.高滴度 COVID-19 恢复期血浆输注的生化原理。
Sci Rep. 2024 Oct 9;14(1):23579. doi: 10.1038/s41598-024-75093-x.
2
Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program.巴西恢复期血浆中 SARS-CoV-2 抗体筛查:一项自愿恢复期供者计划的初步经验教训。
Transfusion. 2020 Dec;60(12):2938-2951. doi: 10.1111/trf.16065. Epub 2020 Sep 16.
3
Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection.COVID-19 恢复期血浆中的抗 SARS-CoV-2 IgG 和 IgA 抗体不会增强病毒感染。
PLoS One. 2022 Mar 8;17(3):e0257930. doi: 10.1371/journal.pone.0257930. eCollection 2022.
4
Blood group O convalescent plasma donations have significantly lower levels of SARS-CoV-2 IgG antibodies compared to blood group A donations.与 A 型血捐献者相比,O 型血恢复期血浆捐献者的 SARS-CoV-2 IgG 抗体水平显著较低。
Transfusion. 2021 Aug;61(8):2245-2249. doi: 10.1111/trf.16524. Epub 2021 May 27.
5
Use of Outpatient-Derived COVID-19 Convalescent Plasma in COVID-19 Patients Before Seroconversion.COVID-19 患者在出现血清转换之前使用门诊获得的 COVID-19 恢复期血浆。
Front Immunol. 2021 Sep 14;12:739037. doi: 10.3389/fimmu.2021.739037. eCollection 2021.
6
Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial.在一项随机试验中,门诊新冠康复期血浆接受者的抗体阈值与住院率降低相关。
JCI Insight. 2024 Mar 14;9(8):e178460. doi: 10.1172/jci.insight.178460.
7
COVID-19 convalescent plasma cohort study: Evaluation of the association between both donor and recipient neutralizing antibody titers and patient outcomes.COVID-19 恢复期血浆队列研究:评估供体和受体中和抗体滴度与患者结局之间的关系。
Transfusion. 2021 Aug;61(8):2295-2306. doi: 10.1111/trf.16573. Epub 2021 Jul 8.
8
Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial.COVID-19 恢复期血浆临床试验中供体抗体滴度的临床预测因子及其与受者抗体反应的相关性。
J Intern Med. 2021 Apr;289(4):559-573. doi: 10.1111/joim.13185. Epub 2020 Nov 3.
9
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.5 例危重症 COVID-19 患者接受恢复期血浆治疗。
JAMA. 2020 Apr 28;323(16):1582-1589. doi: 10.1001/jama.2020.4783.
10
Manufacturing of convalescent plasma of COVID-19 patients: Aspects of quality.COVID-19 患者恢复期血浆的制备:质量方面。
PLoS One. 2020 Dec 22;15(12):e0243967. doi: 10.1371/journal.pone.0243967. eCollection 2020.

本文引用的文献

1
Convalescent Plasma for Covid-19-Induced ARDS in Mechanically Ventilated Patients.恢复期血浆治疗机械通气患者 COVID-19 相关急性呼吸窘迫综合征。
N Engl J Med. 2023 Oct 26;389(17):1590-1600. doi: 10.1056/NEJMoa2209502. Epub 2023 Oct 25.
2
Rates Among Hospitalized Patients With COVID-19 Treated With Convalescent Plasma: A Systematic Review and Meta-Analysis.接受恢复期血浆治疗的新冠肺炎住院患者的发生率:一项系统评价和荟萃分析。
Mayo Clin Proc Innov Qual Outcomes. 2023 Oct 10;7(5):499-513. doi: 10.1016/j.mayocpiqo.2023.09.001. eCollection 2023 Oct.
3
Quality assessment and harmonization of laboratories across Europe for multiple SARS-CoV-2 serology assays.
欧洲多个 SARS-CoV-2 血清学检测实验室的质量评估和协调。
Vox Sang. 2023 Aug;118(8):666-673. doi: 10.1111/vox.13480. Epub 2023 Jul 4.
4
Viral emissions into the air and environment after SARS-CoV-2 human challenge: a phase 1, open label, first-in-human study.SARS-CoV-2 人体挑战后病毒向空气中和环境中的排放:一项 1 期、开放标签、首次人体研究。
Lancet Microbe. 2023 Aug;4(8):e579-e590. doi: 10.1016/S2666-5247(23)00101-5. Epub 2023 Jun 9.
5
SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays.康复者接种 SARS-CoV-2 疫苗可增强对奥密克戎亚变体 BA.1、BA.2 和 BA.5 的中和能力,且可通过血清学检测中的抗-S 抗体浓度进行预测。
Front Immunol. 2023 Apr 25;14:1170759. doi: 10.3389/fimmu.2023.1170759. eCollection 2023.
6
Convalescent plasma for people with COVID-19: a living systematic review.COVID-19 患者恢复期血浆治疗:一项实时系统评价。
Cochrane Database Syst Rev. 2023 May 10;5(5):CD013600. doi: 10.1002/14651858.CD013600.pub6.
7
Intranasal administration of convalescent plasma protects against SARS-CoV-2 infection in hamsters.鼻腔内给予恢复期血浆可预防仓鼠感染 SARS-CoV-2。
EBioMedicine. 2023 Jun;92:104597. doi: 10.1016/j.ebiom.2023.104597. Epub 2023 May 4.
8
Coronavirus Disease 2019 Convalescent Plasma Outpatient Therapy to Prevent Outpatient Hospitalization: A Meta-Analysis of Individual Participant Data From 5 Randomized Trials.新型冠状病毒肺炎恢复期血浆门诊治疗以预防门诊住院:5 项随机试验的个体参与者数据的荟萃分析。
Clin Infect Dis. 2023 Jun 16;76(12):2077-2086. doi: 10.1093/cid/ciad088.
9
Polyclonal immunoglobulins for COVID-19 pre-exposure prophylaxis in immunocompromised patients.用于免疫功能低下患者 COVID-19 暴露前预防的多克隆免疫球蛋白。
Transfus Apher Sci. 2023 Jun;62(3):103648. doi: 10.1016/j.transci.2023.103648. Epub 2023 Jan 31.
10
Convalescent plasma for people with COVID-19: a living systematic review.COVID-19 患者恢复期血浆治疗:一项实时系统评价。
Cochrane Database Syst Rev. 2023 Feb 1;2(2):CD013600. doi: 10.1002/14651858.CD013600.pub5.